Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $11.60 Average PT from Analysts

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) has received an average recommendation of “Buy” from the five analysts that are currently covering the stock, Marketbeat reports. Five investment analysts have rated the stock with a buy rating. The average 1-year price target among analysts that have covered the stock in the last year is $11.60.

A number of analysts have recently weighed in on the stock. The Goldman Sachs Group assumed coverage on shares of Amneal Pharmaceuticals in a report on Friday, June 6th. They set a “buy” rating and a $12.00 price target for the company. Wall Street Zen downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, May 13th.

Hedge Funds Weigh In On Amneal Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Amneal Pharmaceuticals by 6.2% in the 1st quarter. Vanguard Group Inc. now owns 15,762,727 shares of the company’s stock valued at $132,092,000 after acquiring an additional 920,758 shares during the period. Dimensional Fund Advisors LP increased its position in Amneal Pharmaceuticals by 5.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 4,991,702 shares of the company’s stock valued at $39,531,000 after acquiring an additional 278,653 shares during the period. Geode Capital Management LLC increased its position in Amneal Pharmaceuticals by 0.7% in the 4th quarter. Geode Capital Management LLC now owns 3,813,207 shares of the company’s stock valued at $30,207,000 after acquiring an additional 26,536 shares during the period. Nantahala Capital Management LLC increased its position in Amneal Pharmaceuticals by 3.9% in the 1st quarter. Nantahala Capital Management LLC now owns 3,808,561 shares of the company’s stock valued at $31,916,000 after acquiring an additional 143,032 shares during the period. Finally, BlackBarn Capital Partners LP increased its position in Amneal Pharmaceuticals by 1.1% in the 1st quarter. BlackBarn Capital Partners LP now owns 2,881,654 shares of the company’s stock valued at $24,148,000 after acquiring an additional 31,654 shares during the period. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Trading Down 0.2%

Shares of Amneal Pharmaceuticals stock opened at $8.07 on Friday. The company has a 50 day moving average of $7.91 and a 200-day moving average of $7.96. Amneal Pharmaceuticals has a 1-year low of $6.50 and a 1-year high of $9.48. The company has a market cap of $2.53 billion, a PE ratio of -201.70 and a beta of 1.06.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings results on Friday, May 2nd. The company reported $0.19 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.05. Amneal Pharmaceuticals had a negative net margin of 0.46% and a negative return on equity of 188.26%. The company had revenue of $695.42 million during the quarter, compared to the consensus estimate of $714.78 million. Research analysts forecast that Amneal Pharmaceuticals will post 0.53 earnings per share for the current year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.